The cost of validation is planned and controllable. The cost of inadequate validation is often unexpected, disruptive, and substantially higher."
ISOCHECKS investment
↓
Faster, controlled implementation
↓
Earlier clinical service delivery
↓
Earlier return on laboratory investment
Failure to validate a diagnostic service properly can expose laboratories to significant financial, operational, regulatory, and clinical risks.
A robust validation programme typically costs a fraction of the expenses associated with remediation, regulatory findings, or delayed implementation.
Typical Cost: £2,000 to £10,000
Typical Cost: £10,000 to £50,000+
Typical Cost: £25,000 to £100,000+
Typical Cost: £50,000 to £500,000+
Typical Cost : £100,000 to £1M+
This matrix can be used to help laboratories quantify the business risk associated with inadequate or delayed validation activities.
Medium Risk: Non-conformity requiring corrective action (£5k-15k).
Severe Risk: Loss of accreditation or suspended service (£50k+).
Medium Risk: Repeat validation studies (£5k-20k)
Severe Risk: Dedicated recovery project (£50k+)
Medium Risk: 1-3 months (£10k-30k)
Severe Risk: Project failure or cancellation (£100k+)
Medium Risk: Loss of referrals (£25k-100k)
Severe Risk: Contract loss or service decommissioning (£100k+)
Medium Risk: delay in diagnosis
Severe Risk: Potential diagnostic error. Significant incident requiring investigation.
If external specialist support gets your service live weeks earlier, the investment in validation can be small compared with the cost of delay.
New In-Vitro Diagnostics Regulation(IVDR) and ISO 15189, 2022 introduces new compliance challenges for manufacturers and testing laboratories using in-house devices
IVDR now makes concrete demands on laboratories using any laboratory developed test. A lot of medical laboratories are not fully aware of the existing and the new requirements
With a rapidly changing world of therapeutics a lot of devices do not have
clinical performance studies or clinical testing to correlate with the products stated 'intended use' provided with the IVD technical documentation
Verification process delays with Clinical laboratories trying to achieve ISO accreditation leaving new and better devices out of clinical use.
Pathology organizations adopting a multi-site hub and spoke model introduces new implementation challenges for laboratory management